Regulatory effects of Y4 receptor agonist (BVD-74D) on food intake.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Peptides

• Publication date

  2010-09-01

• Fields of study

  Agricultural and Food Sciences, Medicine, Biology

• Identifiers
  DOI 10.1016/j.peptides.2010.06.011PMID 20600429
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neuropeptide Y-family peptides and receptors in the elephant shark, Callorhinchus milii confirm gene duplications before the gnathostome radiation.

  2009cited by this paper
• Molecular recognition of the NPY hormone family by their receptors.

  2008cited by this paper
• Adipokines: the missing link between insulin resistance and obesity.

  2008cited by this paper
• Effect of NPY5R Antagonist MK‐0557 on Weight Regain after Very‐low‐calorie Diet‐induced Weight Loss

  2007cited by this paper
• Neuropeptide Y (NPY) Y2 receptor-selective agonist inhibits food intake and promotes fat metabolism in mice: combined anorectic effects of Y2 and Y4 receptor-selective agonists.

  2007cited by this paper
• Y4 Receptors Mediate the Inhibitory Responses of Pancreatic Polypeptide in Human and Mouse Colon Mucosa

  2006cited by this paper
• [Mutation of mitochondrial DNA in patients with non-alcoholic steatohepatitis].

  2006cited by this paper
• Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar affinity.

  2006cited by this paper
• Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors.

  2005cited by this paper
• Adiponectin and Leptin in Relation to Insulin Sensitivity

  2004cited by this paper
• Pancreatic polypeptide is involved in the regulation of body weight in pima Indian male subjects.

  2004cited by this paper
• Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism.

  2004cited by this paper
• Parasympathetic blockade attenuates augmented pancreatic polypeptide but not insulin secretion in Pima Indians.

  2004cited by this paper
• Characterization of the effects of pancreatic polypeptide in the regulation of energy balance.

  2003cited by this paper
• Diagnosis of Prader-Willi syndrome.

  2003cited by this paper
• Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex

  2003cited by this paper
• Inhibition of food intake in obese subjects by peptide YY3-36.

  2003cited by this paper
• Ligand internalization by cloned neuropeptide Y Y5 receptors excludes Y2 and Y4 receptor-selective peptides.

  2003cited by this paper
• Selective antagonism of the NPY Y5 receptor does not have a major effect on feeding in rats.

  2002cited by this paper
• Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys.

  2001cited by this paper
• Exaggerated pancreatic polypeptide secretion in Pima Indians: can an increased parasympathetic drive to the pancreas contribute to hyperinsulinemia, obesity, and diabetes in humans?

  2001cited by this paper
• Highly selective and potent neuropeptide Y (NPY) Y1 receptor antagonists based on [Pro(30), Tyr(32), Leu(34)]NPY(28-36)-NH2 (BW1911U90).

  2001cited by this paper
• Ethnic Differences in Insulinemia and Sympathetic Tone as Links Between Obesity and Blood Pressure

  2000cited by this paper
• L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist.

  2000cited by this paper
• Molecular characterization of the ligand–receptor interaction of the neuropeptide Y family

  2000cited by this paper
• The FLS mouse: a new inbred strain with spontaneous fatty liver.

  1999cited by this paper
• Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice.

  1999cited by this paper
• Y-receptor subtypes--how many more?

  1997cited by this paper
• GW1229, a novel neuropeptide Y Y1 receptor antagonist, inhibits the vasoconstrictor effect on neuropeptide Y in the hamster microcirculation.

  1997cited by this paper
• Several receptors mediate the antisecretory effect of peptide YY, neuropeptide Y, and pancreatic polypeptide on VIP-induced fluid secretion in the rat jejunum in vivo.

  1997cited by this paper
• Vagal control of digestion: modulation by central neural and peripheral endocrine factors.

  1996cited by this paper
• Molecular Characterization of a Second Mouse Pancreatic Polypeptide Receptor and Its Inactivated Human Homologue*

  1996cited by this paper
• Cloning and Expression of a Novel Neuropeptide Y Receptor*

  1996cited by this paper
• Characterization of neuropeptide Y binding sites in rat brain membrane preparations using [125I][Leu31,Pro34]peptide YY and [125I]peptide YY3-36 as selective Y1 and Y2 radioligands.

  1995cited by this paper
• The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226.

  1994cited by this paper
• Pancreatic polypeptide in dorsal vagal complex stimulates gastric acid secretion and motility in rats.

  1993cited by this paper
• Insulinemia in Children at Low and High Risk of NIDDM

  1993cited by this paper
• Potential regulators of feeding behavior in anorexia nervosa.

  1992cited by this paper
• Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain.

  1990cited by this paper
• Diabetes mellitus in the Pima Indians: incidence, risk factors and pathogenesis.

  1990cited by this paper
• Prader-Willi syndrome

  1989cited by this paper
• Pancreatic polypeptide response to secretin in obesity: effects of glucose intolerance.

  1988cited by this paper
• Fasting- and meal-stimulated peptide hormone concentrations before and after gastric surgery for morbid obesity.

  1986cited by this paper
• Pancreatic polypeptide in Pima Indians: the influence of obesity and diabetes.

  1985cited by this paper
• Neuropeptide Y: stimulation of feeding and drinking by injection into the paraventricular nucleus.

  1984cited by this paper
• Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats.

  1984cited by this paper
• Neuropeptide Y—a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide

  1982cited by this paper
• Reduced pancreatic polypeptide secretion in obese subjects.

  1980cited by this paper
• Low Plasma Levels of Pancreatic Polypeptide in Obesity

  1980cited by this paper
• Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides

  1980cited by this paper
• Pancreatic polypeptide: A possible role in the regulation of food intake in the mouse. Hypothesis

  1977cited by this paper

• The pathway-independent positive allosteric modulator C1 allows for the identification of active Y4 receptor relevant positions

  2026cites this paper
• Illuminating the neuropeptide Y4 receptor and its ligand pancreatic polypeptide from a structural, functional, and therapeutic perspective.

  2024cites this paper
• Illuminating Neuropeptide Y Y4 Receptor Binding: Fluorescent Cyclic Peptides with Subnanomolar Binding Affinity as Novel Molecular Tools

  2024cites this paper
• [3H]UR-JG102-A Radiolabeled Cyclic Peptide with High Affinity and Excellent Selectivity for the Neuropeptide Y Y4 Receptor.

  2023cites this paper
• Stereochemistry-Driven Interactions of α,γ-Peptide Ligands with the Neuropeptide Y Y4-Receptor.

  2023cites this paper
• Cross talk about the role of Neuropeptide Y in CNS disorders and diseases.

  2023cites this paper
• PET Imaging of the Neuropeptide Y System: A Systematic Review

  2022cites this paper
• N-Terminus to Arginine Side-Chain Cyclization of Linear Peptidic Neuropeptide Y Y4 Receptor Ligands Results in Picomolar Binding Constants.

  2021cites this paper
• Heterodimeric analogues of the potent Y1R antagonist 1229U91, lacking one of the pharmacophoric C-terminal structures, retain potent Y1R affinity and show improved selectivity over Y4R.

  2020cites this paper
• Oligopeptides as neuropeptide Y Y4 receptor ligands: identification of a high-affinity tetrapeptide agonist and a hexapeptide antagonist.

  2020cites this paper
• Computational prediction of ligand binding in peptide G-protein coupled receptors

  2019cites this paper
• Photochromic peptidic NPY Y4 receptor ligands.

  2019cites this paper
• Design and evaluation of fluorescent and non-fluorescent bivalent ligands to explore their mode of action at neuropeptide Y receptors

  2019cites this paper
• The human pancreatic polypeptide receptor Y4 : Genetic and functional variation

  2018cites this paper
• Fluorescence- and Radiolabeling of [Lys4,Nle17,30]hPP Yields Molecular Tools for the NPY Y4 Receptor.

  2017cites this paper
• In Search of NPY Y4R Antagonists: Incorporation of Carbamoylated Arginine, Aza-Amino Acids, or d-Amino Acids into Oligopeptides Derived from the C-Termini of the Endogenous Agonists

  2017cites this paper
• High Affinity Agonists of the Neuropeptide Y (NPY) Y4 Receptor Derived from the C-Terminal Pentapeptide of Human Pancreatic Polypeptide (hPP): Synthesis, Stereochemical Discrimination, and Radiolabeling.

  2016cites this paper
• Optically Pure, Structural, and Fluorescent Analogues of a Dimeric Y4 Receptor Agonist Derived by an Olefin Metathesis Approach.

  2016cites this paper
• Receptor Binding Pocket 4 Y Two Hydrophobic Domains of the Human Pancreatic Polypeptide Is Recognized by Signal Transduction :

  2014cites this paper
• Replacement of Thr32 and Gln34 in the C-terminal neuropeptide Y fragment 25-36 by cis-cyclobutane and cis-cyclopentane β-amino acids shifts selectivity toward the Y(4) receptor.

  2013cites this paper
• Chapter 154 – NPY

  2013cites this paper
• Pancreatic Polypeptide Is Recognized by Two Hydrophobic Domains of the Human Y4 Receptor Binding Pocket*

  2013cites this paper
• The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer.

  2011cites this paper
• NPY receptors as potential targets for anti‐obesity drug development

  2011influential citation